COCH (Envoy Medical) Short-Term Debt : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical Short-Term Debt?

Envoy Medical's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

Envoy Medical's annual Short-Term Debt declined from Dec. 2022 ($0.45 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Envoy Medical Short-Term Debt Historical Data

The historical data trend for Envoy Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical Short-Term Debt Chart

Envoy Medical Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

0.45

Envoy Medical Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial							-	-	-	-	-

Envoy Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Envoy Medical Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Envoy Medical's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Envoy Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCH) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4875 White Bear Parkway, White Bear Lake, MN, USA, 55110

Website

https://www.envoymedical.com

Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.